Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating staphylococcus aureus infection

A technology for staphylococcus infection and staphylococcus, which is applied in the field of medicine, can solve problems such as inability of patients to be cured, and achieve the effects of low price, inhibitory activity, and wide source of raw materials

Inactive Publication Date: 2016-08-24
RUIAN PULUO BIOTECH
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

MRSA is resistant to the vast majority of antibacterial drugs, and even vancomycin, which is the most effective clinical anti-drug-resistant bacteria, has begun to develop drug resistance. Once MRSA develops to the extent of universal resistance to vancomycin, patients infected with MRSA will Facing a dangerous situation with no cure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating staphylococcus aureus infection
  • Pharmaceutical composition for treating staphylococcus aureus infection
  • Pharmaceutical composition for treating staphylococcus aureus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] The pharmaceutical composition was formulated according to Table 1 below.

[0034] Table 1

[0035] combination

Chlorogenic acid (mg)

Glycyrrhizic acid (mg)

Erythromycin (mg)

Vancomycin (mg)

A

30

0

0

0

B

0

10

0

0

C

40

10

0

0

D

45

10

0

0

E

50

10

10

0

F

30

10

0

10

[0036] Determination of minimum inhibitory concentration (MIC):

[0037] Take the compositions of each group prepared according to Table 1 and carry out a series of multiple dilutions in the MH broth medium, and adjust the initial bacterial concentration to 1.0×10 6 CFU / ml. After incubating at 35°C for 24 hours, the lowest concentration of antibacterial drug without precipitation is its minimum inhibitory concentration (MIC). Erythromycin (ERY) and vancomycin (VAN) were used as controls.

[0038] The results of the in vitro antibacterial test are shown in Table 2.

[...

Embodiment 2

[0046] Balb / C mouse sepsis model: established according to the method of cecal ligation and puncture (CLP). For the establishment method, please refer to the literature J.Vis.Exp.(62), e3926, doi: 10.3791 / 3926 (2012). Animal survival time was calculated from the completion of surgery.

[0047] The composition of the present invention (Group C in Example 1) was dissolved in physiological saline, and administered by intraperitoneal injection according to the following doses. The first dose was given 24 hours after CLP, and then every 24 hours for a total of 3 doses. Divided into 3 experimental groups, the doses of each group were 2.0, 4.0, and 8.0 mg / kg body weight respectively.

[0048] The control group was only injected with the same volume of normal saline.

[0049] The results showed that 2.0, 4.0, 8.0 mg / kg body weight compositions increased the eighth day survival rate of septic animals from 21% to 50%, 57%, 85%, respectively. These results indicate that the compositio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for treating staphylococcus aureus infection. The pharmaceutical composition contains chlorogenic acid and glycyrrhizic acid. The pharmaceutical composition substantially inhibits staphylococcus aureus activity and substantially improves staphylococcus aureus inhibition effects of an antibiotic. The invention also provides a use of the pharmaceutical composition. The pharmaceutical composition is used for preparation of a drug for treating staphylococcus aureus infection and / or preparation of a drug for killing staphylococcus aureus in the environment.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a pharmaceutical composition for treating Staphylococcus aureus infection. Background technique [0002] Staphylococcus aureus infection is a common bacterial infectious disease, mostly manifested as skin and soft tissue infection, and can also lead to serious and life-threatening sepsis, endocarditis, pneumonia, meningitis, etc.; in addition, it can also cause foreign body-related infections , urinary tract infection, osteomyelitis, arthritis, enteritis, etc. Staphylococcus can be cross-transmitted and cause epidemics in hospitals, especially in surgery, burn departments, and neonatal wards. Due to the rapid spread, difficulty in control and serious consequences, it was called "staphylococcal plague" in the past. In the 1950s, nosocomial infections and staphylococcal infections became synonymous; in the 1960s, the prevalence of staphylococcal infections in hospitals declined ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/216A61K31/704A61K38/14A61K31/7048A61P31/04A61K31/5383
Inventor 杨钟华
Owner RUIAN PULUO BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com